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Platelet alloantibody in multiply transfused thrombocytopenic 
patients. 
Wan Haslindawani W M, Rapiaah M. 
From Department of Hematology, Hospital Science of Malaysia. 
Abstracts 
BACKGROUND: Multiply transfused patients are frequently subjected to platelet 
alloimmunization. These platelet alloantibodies produced can result in refractoriness to 
platelet transfusion. 
STUDY DESIGN AND METHODS: Ninety five thrombocytopenic (platelet count 
<1 00 x 1 09/1) and multilply transfused (more than 2 times transfusion of any blood 
component with last transfusion more than 2 weeks prior to the study) patients were 
recruited prospectively. The blood samples were tested using a Solid Phase system 
(Capture P). 
RESULTS: There were 45 males (47.4%) and 50 females (52.6%) recruited with ages 
from 3 to 90 years. The frequency of transfusions ranged from 10-168. Seven patients 
(7.4%) were detected to have platelet alloantibodies, predominantly anti-HPA-5b in 4 
patients (4.2%). Three of them (3.2%) showed a non-specific pattern. Six patients (6.3%) 
had received packed cells less than 20 units and another 1 (1.1%) received more than 20 
units of packed cells. Four patients (4.2%) received platelet transfusion of less than 20 
units and another 3 patients (3.2%) received more than 20 unit platelets. 
CONCLUSION: The study may have future implications for the selection of platelet 
donors for alloimmunized recipients in HUSM. 
Keywords : multiply transfused , thrombocytopenia , platelet alloantibody 
INTRODUCTION 
Alloimmunization is an immune response that happens when body reacts to foreign 
antigen (from donor's blood) and creates antibodies against them. Patients receiving 
leucocytes reduced blood product are at much lower risk for refractoriness to platelet 
transfusion than are recipients of blood that is not leucocytes reduced. 1 
Alloimmunization in polytransfused patient is a well known observation which very 
often results in refractoriness to platelet transfusions. Alloantibodies are usually 
directed against HLA antigens and their frequency is evaluated between 20 to 70 %. 
Alloantibodies may also be directed against platelet-specific antigens but their 
frequency is controversial. 2 Alloantibodies against platelet membrane glycoprotein 
are a common cause for febrile non hemolytic transfusion reactions.3 
Patients who are given platelets over longer periods of time, such as those under 
treatment for hematologic or oncologic disorders, may develop a condition called 
refractoriness to platelet transfusions. 4 These refractory patients may become resistant 
to subsequent platelet transfusion thus increasing the risk of spontaneous bleeding.1 A 
patient with previous platelet refractoriness secondary to alloimmunization may need 
HLA-matched or crossmatched platelets for transfusion support. 5 
MATERIALS AND METHODS 
This was a cross sectional study conducted at Hospital Universiti Sains Malaysia from 
June 2003 to June 2004.This study was approved by the School of Medical Sciences 
Research and Ethical Committee. All subjects gave an informed written consent 
Patient 
Subjects were recruited from wards, medical clinic and transfusion records from blood 
bank. Subjects with history of multiple transfusions (more than twice of any of blood 
components, more than 2 weeks but not more than 2 years of their last transfusions) and 
thrombocytopenia (platelet count less than 100 x 1 0911). Patients who were on heparin or 
with autoimmune diseases such as ITP, SLE or AIHA were excluded. Selected patients 
were then given written consent. 7 mls of peripheral blood were taken and collected in 
EDT A bottles. Two mls of the peripheral blood for FBP and 5 mls for antibody detection. 
The analysis was performed at the Haematology Laboratory, HUSM. 
Laboratory tests 
The laboratory tests performed were: 
1. Full blood picture 
2. Screening test for platelet antibodies. 
3. Confirmation test. 
Full blood picture was done as a screening to confirm thrombocytopenia Screening was 
performed by using Capture -P Solid phase system from Immunocor Inc .. Donor platelets 
were used as a source of platelets. Positive cases, were confrrmed by the Capture-P 
Ready Screen test. 
Statistical analysis 
The data was analysed by using SPSS software, Descriptive analysis and Chi-square (to 
associate the presence of antibody with age, diagnosis, number of plasma and packed 
cells transfused). 
RESULTS 
Of the 95 studied patients, demographic data as shown in Table I. Platelet alloantibodies 
were detected in 7 (7 .4%) patients. Six of them were diagnosed to have haematological 
disorders (3 were diagnosed to have Aplastic Anaemia, 1 with AML, 1 with NHL and 
another 1 with Familial thrombocytopenia). Another 1 patient was involved in Motor 
Vehicle Accident. The age of the patients were between 12 years old to 75 years old. 
There were 2 males and 5 females. All of them were Malays. The number of packed cells 
that had been transfused was between 1 unit to 25 units. The number of platelet 
concentrate that had been transfused was between 1 unit to 139 units. Four (4.2%) 
patients were found to have anti-HPA 5b and another 3 (3.2%) patients were found to 
have non-specific pattern. Table 2 
There was no significance relationship between presence of platelet alloantibody 
and age of patient (P value > 0.05). This is probably due to small number of patient 
recruited in this study. 
There was also no significant relationship between presence of platelet 
alloantibody with sex and race of the patients. However all patients with platelet 
alloantibody were Malays and 2 of them were males and the rest were females. 
The number of packed cells and platelet concentrate transfused also showed that it 
was not associated with the presence of platelet alloantibody. Table 3 
DISCUSSIONS 
The purpose of this prospective study was to determine the frequency and specificity of 
platelet alloantibody in these multiply transfused patients and also to correlate with any 
underlying disease, age of patients, sex of patients, race of patients, and also the numbers 
and types of blood components given to the patients with the development of platelet 
antibodies. 
The majority of the patients were diagnosed as haematological disorders (66.3%) and the 
remaining 33.7% were diagnosed to have non-haematological disorders (end-stage renal 
failure, chronic liver disease and others). In these non-haematological patients, most of 
them were having fever and sepsis during platelet alloantibody tests was undertaken. 
In this study, seven (7.4%) of the patients were found to have platelet alloantibody. The 
anti-HPA-5b was found to be positive in 4 (4.2%) of these patients and 3 (3.1%) of them 
were female and only 1 (1.1%) was male. Another 3.2% of patients were shown to have 
non-specific pattern of platelet alloantibody. 
The finding of anti-HPA-Sb as the highest frequency in this study was similar with the 
finding by Kiefel et al. 6 which had shown that the antibody specificity found with the 
highest frequency was anti-HP A-5b (Br~. Other specificities found (in decreasing order 
of frequency) were anti-HP A-1 b (PlA2), anti-HP A-Sa (Brb), anti-HP A-2b (Ko8), and anti-
HPA-1a (PlA1). 
Reports about frequency and specificity of platelet-specific alloantibodies in 
multitransfused patients are rare. This is due to the fact that in such patients platelet-
specific antibodies will occur rarely without HLA antibodies, thus complicating their 
identification and especially their specificities. Murphy et al. . 7The possibility of having 
the non-specific pattern of platelet alloantibodies in this study (3 .2%) may be due to the 
presence of anti-HLA especially anti-HLA 1 which is the commonest to be presence in 
leukaemia patients. 
In the United States, HLA class 1 antibodies were involved in majority of the 
alloimmunized cases, whereas platelet specific antigens (e.g. HP A) were involved in 
approximately 10-20% of refractory cases. Both types of antibodies were involved in 
approximately 5% of cases. A single random RBC or platelet transfusion induces anti-
HLA antibodies in fewer than 10% of recipients (most likely related to the tolerogenic 
effect of blood transfusions). If patients have more than 20 transfusions, they become 
sensitized in increasing proportions; after 50 transfusions, the majority (as many as 70%) 
of patients have anti-HLA antibodies. The presence of HLA antibodies showed better 
correlation with platelet refractoriness than antibodies directed against platelet-specific 
antigens. The most common platelet-specific antibody was directed against the HPA-la 
antigen present on glycoprotein 11 a 8 
Refractoriness to platelet transfusions due to platelet-specific antibodies is often difficult 
to assess since, if they developed anti-HLA antibodies, such patients must be transfused 
with HLA-matched platelets. Nevertheless, platelet-specific antibodies (HP A-1 a, HP A-1 b, 
HPA-2b, HPA-3a) have already been found to be responsible for platelet refractoriness.9 
Study done by Uhrynowska et al. 2, showed that the efficacy of platelet transfusions was 
difficult to assess due to other non haematological factors which could contribute to 
refractoriness. 10 
Alloantibody specificities encountered in multiply transfused patients differ considerably 
from those in patients with PTP and maternal alloantibodies in NAIT. Two latters 
conditions, anti-HPA-1a was the platelet antigen, most frequently encountered among 
white patients Kroll et al. 11, whereas anti-HP A-1 b and anti-HP A-5b were prevalent 
among multiply transfused patients. In a large series of multiparous blood donor, anti-
HPA-5b was the most common alloantibody Kalinowski et al.12• However, anti-HPA-la 
was the second most frequent alloantibody in that donor group, which reflects the 
different mode of immunization in that study population (pregnancy). 
The frequency of platelet-specific antibodies in multitransfused patients and their 
implication in platelet transfusion refractoriness has been a matter of controversy for 
years. The main reasons are the difficulties encountered in differentiating between HLA-
and platelet-specific antibodies and, within platelet-specific antibodies, between auto- or 
alloantibodies, using the available platelet antiglobulin test Schnaidt et al. 13• Thus, data 
suggesting a frequency of platelet-specific antibodies in about 20% of patient were 
obtained indirectly, such as different reaction patterns of sera tested on lymphocytes and 
platelets of the same individual as well as transfusion failures with HLA-matched 
platelets Pegels et al.14• In the recent years, capture assays were developed, using 
immobilized platelet membrane glycoprotein (GP) carrying the antigens under 
investigation to avoid using whole platelets. These assays overcome the difficulties in 
differentiating platelet-reactive antibody mixtures and allow determination of antibody 
specificity. 
It is known that previous pregnancies predispose to the production of multispecific HLA 
antibodies during transfusion therapy. 15 However, there is no evidence to suggest for pre-
immunization due to pregnancies as a main cause for the presence of platelet-specific 
alloantibodies in patients presenting with multispecific HLA antibodies. 13 
Multispecific HLA antibodies are a prerequisite for transfusion-induced platelet-specific 
alloantibodies. Since only a small percentage of haematologic-oncologic patients 
undergoing platelet transfusion therapy develop such multispecific HLA-antibodies 
Brand et al. 15, Schnaidt et al. 13 have concluded that frequency of platelet-specific 
alloantibodies and their impact on platelet refractoriness with regard to all patients 
transfused was low. They also believed that, nonimmunological factors were more often 
implicated in platelet refractoriness than platelet-specific alloantibodies. For the group of 
highly HLA-immunized patients in need for HLA-matched single donor platelets, 
however, there are only as many as 25% will have additional platelet-specific 
alloantibodies. These platelet-specific alloantibodies will prohibit satisfactory transfusion 
results ifHLA-matched but HPA-incompatible platelets are transfused. 
CONCLUSIONS 
Alloimmunization in polytransfused patients is a well known observation which often 
results in decreased responses to subsequent platelet transfusions and failure to achieve 
haemostatic levels of platelets that may preclude these patients from important 
procedures, including bone marrow transplantation. Our data showed a significant rate of 
platelet alloimunization (7 .4%) in multiply transfused thrombocytopenic patients. 
Perhaps more samples are needed to analyse the full spectrum of platelet 
alloimmunizations, especially platelet specific alloantibody. 
From our data, the most frequent platelet alloantibody was anti-HPA-Sb. For future 
transfusion, we recommend that patients receive compatible platelets after ruling out 
nonimmune, autoimmune and drug-related causes of platelet refractoriness since 
compatible platelets can significantly improve the platelet recovery. 
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Table 1 Demographic data of patients with multiple transfused thrombocytopenia 
Demographic data Number of patients (n) (%) 
Total Patients 95 
Diagnosis 
63 Haematological disorders 66.3% 
Non-Haematological disorders 7 7.4% 
-Chronic Liver Disease 
-ESRD 11 11.6% 
-Others 3 3.2% 
11 11.6% 
Gender 
Female 
Male 50 52.6% 
45 47.4% 
Ethnic 
Malay 
88 Chinese 92.6% 
Indian 5 5.3% 
Others 1 1.1% 
1 1.1% 
Age 
0-20 years 
28 21-40 years 29.5% 
41-60 years 15 15.8% 
61-80 years 32 33.7% 
>80 years 17 17.9% 
3 3.2% 
Table 2 Data of patients with platelet alloantibodies 
Patient Patient Patient 3 Patient Patient Patient Patient 
1 2 4 5 6 7 
Age 75 46 12 17 50 50 39 
Sex Male Female Female Male Female Female Female 
Race Malay Malay Malay Malay Malay Malay Malay 
Diagnosis NHL Aplastic Familial MVA Aplastic Aplastic AML 
anaemia tbrombocy- anaemia anaemia 
topenia 
Number of 25 0 11 10 6 5 7 
packed cells 
transfused 
Number of 39 8 25 16 0 24 139 
platelet 
transfused 
Type of Non HPA-5b HPA-5b HPA- No No HPA-
alloantibody specific Sb specific specific Sb 
pattern pattern pattern 
Table 3 Association between presence of platelet alloantibody with age, sex, race, 
number of packed cells and plasma transfusion. 
Independant Absence of Presence of Statistical Tests P value 
alloantibody alloantibody 
Age 
0-40 40 3 0.06 0.807 
>40 48 4 
Gender 
Female 45 5 1.19 0.275 
Male 43 2 
Ethnic 
Malay 81 7 0.00 0.999 
Non Malay 7 0 
Number of packed 
cells transfused 0.87 0.350 
<20 83 6 
>20 5 1 
Number of platelet 
transfused 0.008 0.927 
<20 50 4 
>20 38 3 
(Level of significance, p< 0.05) 
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ABSTRAK 
Pesakit yang kerap menenma pemindahan darah adalah terdedah kepada platelet 
alloimmunisasi. Alloantibodi kepada platelet akan menyebabkan kegagalan kepada 
transfusi platelet. Tujuan kaj ian ini dijalankan adalah untuk mengesan alloantibodi 
kepada platelet didalam pesakit yang kerap menerima transfusi darah di HUSM. 
Sebanyak sembilan puluh lima pesakit thrombocytopenia (kiraan platelet< 100 x 1009/l) 
yang kerap menerima transfusi darah (lebih dari dua transfusi darah dari sebarang 
komponen dan tarikh terakhir pemindahan sekurang-kurangnya dua minggu dari tarikh 
kajian) diambil secara prospektif. Sampel darah diuji dengan menggunakan "Solid Phase 
System" (Capture-P). 
Seramai 45 lelaki (47.4o/o) dan 50 percn1puan (52.6%) termasuk dalam kajian ini. Jarak 
umur adalah diantara 3 hingga 90 tahun. Kekcrapan transfusi darah adalah dian tara 10 
hingga 168 kali. Tujuh pesakit (7 .4o/o) didapati alloantibodi kepada platelet, terutarnanya 
anti-HPA-5b (4.2%). Tiga pesakit (3.2%) daripada n1ereka n1enunjukkan naten vanp 
l J ·~ 
tidak khusus. Enam pesakit (6.3%) telah menerima transfusi sel darah merah padat 
kurang daripada 20 unit dan seorang pesakit ( 1.1 %) telah menerima transfusi lcbih 
daripada 20 unit sel darah merah pad at. En1pat pesakit ( 4.2o/o) mencrima transfusi platelet 
kurang dari 20 tmit dan tiga pesakit (3.2o/o) mencrin1a lebih dari 20 unit platelet. 
Keputusan ini membuktikan implikasi di masa hadapan dalam memilih penderma platelet 
yang mempunyai alloimmunisasi. 
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ABSTRACT 
Multiply transfused patients are frequently subjected to platelet alloimmunization. These 
platelet alloantibodies produced can result in refractoriness to platelet transfusion. The 
aim of this study is to detect the presence of anti-platelet alloantibodies in multiply 
transfused thrombocytopenic patients in HUSM 
Ninety five thrombocytopenic (platelet count <1 00 x I 09 /1) and multilply transfused 
(more than 2 times transfusion of any blood component with last transfusion more than 2 
weeks prior to the study) patients were recruited prospectively. The blood samples were 
tested using a Solid Phase system (Capture P). 
There \Verc 45 rnalcs (47.4%) and 50 fcrnales (52.6%) recruited with ages fron1 3 to 90 
years. The frequency of transfusions ranged from 10-168. Seven patients (7.4o/o} were 
detected to have platelet alloantibodies, predominantly anti .. HPA-5b in 4 patients ( 4.2o/o). 
Three of them (3.2°/o) showed a non-specific pattern. Six patients (6.3o/o) had received 
packed cells less than 20 units and another 1 ( 1.1%) received more than 20 units of 
packed cells. Four patients ( 4.2%) received platelet transfusion of less than 20 units and 
another 3 patients (3.2o/o) received more than 20 unit platelets. 
Xll 
The study may have future implications for the selection of platelet donors for 
alloimmunized recipients in HUSM. 
X Ill 
Chapter 1 
INTRODUCTION 
·,. 
1.0 INTRODUCTION 
1.1. Platelets 
1.1.1. Formation of blood platelets 
Blood platelets are fragments of the cytoplasm of megakaryocytes, hence there are non 
nucleated and are formed chiefly in the bone marrow. Most of the available knowledge 
about thron1bopoeisis is derived from bone marrow culture experiments, or frOin 
observations in humans and animals recovering from drug induced tlu-on1bocytopenia, 
which are conditions under which physiological mechanisms may not prevail. 
Megakaryocytes are derived fron1 pluripotential sten1 cells, as the earliest recognized 
platelet precursors is a burst-fonning unit denoted BFU-Meg. Under the influence of 
thrombopoeitin (Tpo) and cytokines such as IL-3 and IL- I I, the BFU-Meg develop into 
n1egakaryocyte colony-forn1ing units (CFU-Meg). 
The con1n1itted progenitor cells cease to undergo classical n1itosis, developing instead by 
endo1nitotic reduplicative, where nuclei divide but not the celL the n1orphological and 
biochen1ical features of n1egakaryoblasts and then n1egakaryocytcs. Their ploidy states 
progress from 2N up to 32N or even 64N. Their dian1ctcrs increase fron1 6-20~tn1 
(tnegakaryoblasts) to around 60~L111 (fully. n1ature n1egakaryocyte) associated \vith 
proliferation of the characteristic platelet granules (a-granules and dense bodies) and 
membrane glycoproteins, which are vital to platelet functions. The membrane 
glycoproteins have different functions for example glycoprotein lib-lila involves in 
platelet aggregations and glycoprotein Ib involves in platelet adhesions to subendothelial 
microfibrills. 
The rapid increase in cytoplasm is accommodated by progressive folding, or 
invagination, of its membrane and it has been proposed, that this process accounts for the 
appearance of den1arcation 1nen1branes, which eventually form the boundary of 
individual platelets. A fully mature 1negakaryocyte begins to extend pseudopodia, which 
penetrate through the walls of adjacent individual platelets or larger cytoplastnic 
fragments. The latter 'proplatelets' are transported through the bloodstream via the heart 
to the lungs, where final 1nechanical fragtnentation is accon1plished in the puln1onary 
1nicrocirculation. Each tnegakaryocyte gives rise to as n1any as 3000 platelets. 
Around 20-30% of 'circulating' platelets appear to be sequestered in the spleen, although 
it is not known if the splenic pool represents the newly released cells. The nonnal life 
span of platelets ranges between 8 and 14 days. The platelet count in the peripheral blood 
is in the range 150-400 x 1 09/l in nonnal subjects. (Hoffbrand et al., 1999) 
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1.1.2. Structure and function of the blood platelets. 
Platelets that have been fixed immediately after ren1oval fron1 the body appear under the 
electron n1icroscope as smooth, biconvex discs with a diatneter of 2-4J.tn1. 
The platelet plasn1a tnembrane is vital to the cells function for two reasons. Firstly, it 
contains a nun1ber of specific glycoprotein (GP) receptors, tlu·ough which platelets 
interact with aggregating agents, inhibitors, coagulation factors (such as fibrinogen, von 
Willibrand factor and throtnbin) and consequently, \Vith the vessel wall and \Vith each 
other. Secondly, the platelet tnetnbrane also contains phospholipids. \vhich are concerned 
\Vith prostaglandin synthesis and calciun1 n1obilization \Vithin the celL and \Vith the 
generation and localization of procoagulant activity on the outer surface of the platelet. 
(Hoffbrand ct al., 1999) 
, 
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1.2 Blood products 
A blood product is defined as any therapeutic substance prepared fron1 human blood. 
Whole blood is unseparated blood collected into an approved container containino an 
b 
anticoagulant-preservative solution. Whole blood is obtained fron1 lnnnan blood donors 
by venesection. Whole blood may be suitable for transfusion in many clinical situations, 
such as red cells replacement in acute blood loss where there is also hypovolaen1ia. 
However, the whole blood is also a source of other in1portant con1ponents and the 
separation of whole blood into its constituent component-red cells, platelets and plasn1a is 
widely practiced for use \Vhen these cotnponents only are specifically required. 
A blood cotnponent is a constituent of blood, separated fron1 whole blood into red cell 
concentrates, plasn1a and plastna cotnponents such as fresh frozen plasma {FFP) and 
cryoprecipitate as \Vell as platelet concentrate. 
(Etntnanuel, 200 1) 
For platelet concentrates, there arc two types which are available for transfusion: 
1. platelet frotn randon1 donor 
2. aphercsis platelet. 
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Platelets are prepared from whole blood of apparently healthy donors by differenti~l 
centrifugation, while apheresis platelets are harvested from individual donors through 
apheresis with minimal or no contamination by leucocytes or red cells. Although platelets 
are the predominant cellular component, both products also contain significant amounts 
of red cells, leucocytes and plasma. All these blood cotnponents in platelet concentrates 
are potentially in1munogenic and can lead to various immunological and clinical 
consequences in transfusion recipients. (Kao et al., 2000) 
) 
1.3. Blood transfusion 
1.3.1. Indications 
Blood transfusion involves the infusion of whole blood or the blood components frotn 
one individual (the donor) to another (the recipient). 
For the whole blood, it is usually reserved for red cell replacetnent in acute blood loss 
with hypovolaen1ia, for example in trautnatic or surgical blood loss, or severe 
gastrointestinal or uterine haetnorrhage. It is also used in exchange transfusion for the 
case of neonatal jaundice. Son1etimes it is given to the patients needing red cell 
transfusions \Vhere red cell concentrates are not available. 
Red cell concentrates are the treatn1ent of choice in chronically anacn1ic patients who 
require transfusion. In older subjects, a diuretic is often given sirnultaneously and the 
infusion should be sufficiently slow to avoid circulatory overload. In the tnajority of 
patients with deficiency anaetnias appropriate therapy \Vith iron, folate or vitan1in 13 12 is 
sufficient and red cell transfusions are seldon1 required. In chronic anaen1ias \vhich do not 
respond to haen1atinics, transfusion should be avoided unless the patient is at risk fronl, 
or incapacitated by, the anaen1ia. This concentrates is also used v.;ith crystalloid 
rcplacerncnt fluids or colloid solution in acute blood loss. 
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Platelet concentrates as mentioned earlier are harvested by cell separators or fron1 
individual donor units of blood. These concentrates are indicated in severely 
thrombocytopenic patients or patients with platelet dysfunctions in established 
haemorrhage or prophylactically to prevent bleeding for example during intensive 
myelotoxic che1notherapy to keep the platelet count above 5-I 0 X I 09/1. Their 111ost 
in1portant use is therefore in the support of patients with severe bone n1m·row failure for 
example due to acute leukaen1ia, aplastic anae1nia, 1nyelodysplasia or bone nlaiTow 
transplantation. If fever, infection or concurrent coagulopathy is present or the platelet 
count is falling rapidly or potential bleeding sites for exmnple surgical wounds are 
present, the platelet count should be kept more than 20 X 1 09/l. Platelets n1ay also be 
needed for patients vvith platelet functional disorders, follovving tnassive blood 
transfusion during cardiopuhnonary by-pass surgery vvith bleeding not due to surgically 
correctable disorders and for patients with disscrninated intravascular coagulation and 
bleeding. Platelets arc not usually used in itnnllme thrornbocytopenias but n1ay be given 
in auto-in1n1unc thrornbocytopcnia vvith n1ajor haen1orrhage and in neonatal alloimmunc 
thron1bocytopenia. 
For the fresh frozen plasn1a, it is a rapidly frozen plas1na separated fron1 fresh blood and 
its 111ain use is for the replacen1ent of coagulation factors, for exan1ple \Vhen spcci fie 
concentrates arc unavailable or after n1assivc transfusions. liver disease. warfarin 
anticoagulant overdose and disserninated intravascular coagulation (DIC). It is also 
indicated in thrornbotic thron1bocytopenic purpura (TTP). 
7 
Cryoprecipitate is obtained by thawing fresh frozen plasma at 4oC and contained factor 
VIII, factor XIII, von Willebrand factors (vWF), fibronectin and fibrinogen. It is used 
widely as replacement therapy in haemophilia A and von willebrand' s disease before 
more purified preparations of factor VIII became available. It is also used as a source of 
fibrinogen in acquired coagulopathies eg DIC. (Emmanuel, 2001) 
1.3.2. Adverse effects of blood transfusion 
Transfusion reactions occur in 7-10% of all recipients of blood or blood components. The 
majority of them are minor reactions, of which 10% are hemolytic and 90% are non 
hemolytic reactions. Transfusion reactions may be divided into acute(< 24 hours) and 
delayed(> 24 hours), as shown in Table 1.0 and Table 1.2. 
Table 1.1 Acute Transfusion Reactions. 
Immunologic Etiology 
Haemolytic transfusion reactions (HTR ABO incompatibility 
Febrile non-haemolytic transfusion reaction Cytokines ,antileucocyte antibodies 
(FNHTR) 
Allergic Antibodies to plasma protein 
Anaphylaxis Antibodies to IgA 
Transfusion related acute lung injury Antibodies to leucocytes or to complement 
(TRALI) activation 
Non Immunologic 
Marked fever with shock Bacterial contamination 
Atypical reaction with hypotension Associated with ACE inhibitors 
Congestive cardiac failure Volume overload 
Air embolism Air infusion via line 
Hypocalcaemia Citrate toxicity 
----
'---· 
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Hypothermia Rapid infusion of cold blood 
Hypokalaemia and hyperkalaemia Red cell storage 
Table 1.2 Delayed adverse reaction to transfusion (>24 hours). 
Immunologic Etiology 
Alloimmunization to red blood cell (RBC), Exposure to antigen of donor origin-
white blood cell (WBC) and platelets plasma protein, human leucocyte antigen 
(HLA) 
Hemolytic Anamnestic antibodies to RBC antigens 
Transfusion associated graft versus host Engraftment of transfused functional 
disease (TAGvHD) lymphocytes Not well understood 
Post transfusion purpura Antiplatelet antibodies 
Non Immunologic 
Iron overload Multiple transfusion 
Transfusion transmitted disease Hepatitis, hun1an in1munodeficicncy VlfUS 
(HIV), Cytomegalovirus etc 
(En1manuel, 2001) 
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1.4. Causes of thrombocytopenia 
Thrombocytopenia is defmed as a platelet count of less than 150 X 1 09/1. There are many 
causes of thrombocytopenia which can be divided into non-immtme thrombocytopenia 
and immune thrombocytopenia as shown in Table 1.3. 
Table 1.3 Causes of thrombocytopenia. 
A. Non immune thrombocytopenia is associated with : 
-bone marrow transplant 
-sepSIS 
-disseminated intravascular coagulopathy 
-splenomegaly 
-fever 
-leukaemia/anaemia 
-antibiotic therapy 
-clinical bleeding 
-hepatomegaly 
-liver disease 
-chemotherapy 
-heart valves replacement 
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B. Immune thrombocytopenia: 
1. Autoimmune thrombocytopenia this occurs because of the presence of autoantibodies 
to the patient's own platelet as in idiopathic thrombocytopenic purpura and acute 
thrombocytopenic purpura. 
2. Alloimmune thrombocytopenic purpura which may be associated with multiple 
exposures to similar cellular antigens as in post transfusion purpura and neonatal 
alloimmune thrombocytopenia. 
3. Drug induced which may occur following the administration of heparin, quinine, 
sulpha drugs and others. 
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1.5 •. Platelet alloantigens and alloantibodies. 
Platelet alloantigens are defined by alloantibodies directed against genetically determined 
molecular variants of proteins or carbohydrates on the platelet membrane. The 
alloantibodies are elicited in normal individuals upon exposure to the alloantigen usually 
during pregnancy and in blood transfusion, or, rarely, by bone marrow transplantation. 
These alloantibodies bind to the target platelet alloantigens, resulting in immuno-
mediated platelet phagocytosis. 
Three major group of alloantigens are present on platelets: 
1. Blood group antigens 
2. Platelet-specific antigens 
3. HLA's 
There are different types of clinically relevant platelet alloantigens. Alloantigens shared 
with other blood cells and tissues are referred to as Type I antigens. Among these are the 
glycoconjugates of the blood group ABH system and the highly polymorphic HLA 
class I molecules. Type II alloantigens are more or less specific to platelets and are 
conventionally called platelet-specific alloantigens. It is well documented that platelet-
specific antibodies against type II alloantigens play a role in the pathological mechanism 
of neonatal alloimmune thrombocytopenia (NAIT), post-transfusion purpura (PTP) and 
post-transfusion refractoriness (PTR). In contrast, platelet antibodies against type 1 
alloantigens seem to be restricted to PTR. (Santoso et al., 2003) 
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Blood group antigens on platelets include ABH, Lewis, Ii and P antigens. These antigens 
are present in platelet membrane glycoproteins (Santoso S et al, 1991 ). Antibodies to 
ABO, Lewis, and P antigens often develop spontaneously in antigen-negative persons, 
and antibodies to I antigens are cold reacting autoantibodies (Mollison PL et al, 1993 ). 
It is generally assumed that the expression of ABH antigens on platelets is too weak that 
anti-A, anti-B isoagglutinins cannot affect considerably the survival time of ABO-
incompatible platelets (Santoso et al, 2003) and although the impact of ABO 
compatibility on post-transfusion platelet recovery, albeit small, has been demonstrated 
(Lee EJ et al., 1989). 
Platelet membrane glycoproteins contain antigenic epitopes that are not found on other 
types of blood cells. More than 20 such platelet specific alloantigens have been identified 
(Kunicki et al, 1992), and many have been well characterized at the molecular level 
(Newman et al, 1995). Many platelet-specific alloantigens have been found on other cells 
and tissues as well such as the cell adhesion receptor and intergrins. Six diallelic 
alloantigen systems (HP A-l-5 and HP A-15) and a number of low frequency antigens 
(HPA-6W-14W, HPA-16W) have been described. Currently, six platelet membrane 
glycoproteins GPia, GPiba , GPibB , GPIIb, GPIIIa and GPI-linked CD109 have been 
identified as carriers of platelet alloantigenic determinants (Santoso et al., 2003). These 
platelet specific alloantigens are present in dimorphic forms, and the allelic frequencies 
are equally distributed in a high-frequency public form and a low-frequency private form 
(Kim et al., 1995). They can elicit the production of antibodies through transfusion and 
pregnancy. The development of such antibodies can result in three clinical conditions: 
14 
1. Neonatal al1oimmune thrombocytopenia- mother becomes immunized to platelets of 
fetus and give birth to thrombocytopenic infants; 
2. Post-transfusion purpura- patients become immunized to platelet-specific alloantigens 
after blood transfusion and develop thrombocytopenia; 
3. Transfusion-associated alloimmune thrombocytopenia- patients receive multiple 
platelet transfusions and become refractory to random-donor platelets. (Mcfarland, 1996) 
Table 1.4. Human Platelet-Specific Antigen Systems (Adapted from Kim et al, 
1995) 
- -------- ----~ -- -•- ---·--------~ ----------- --
Platelet i Protein I I Antigen Antigen 1 Synonyms i Alleles I Antigen Frequency i System I 
- -· --------- ------
--- ---r -- - -. -------
i , HPA-1a 
I I := PIA1 97% HPA-1 ! GPIIIa 1PIA,zw HPA-1b 26°/o 
= PIA2 
HPA-2 GPib Ko, Sib HPA-2a 
99o/o 
HPA-2b 14°/o 
HPA-3 GPIIb Bak, Lek HPA-3a 85°k HPA-3b 66% 
HPA-4 GPIIa Pen, Yuk HPA-4a >99°/o HPA-4b <1°/o 
HPA-5 GPia 'Br, Hcl Zav HPA-5a 
99o/o 
:HPA-5b 20o/o 
The platelet membrane glycoproteins (GPs) that carry the human platelet antigen (HPA) 
epitopes play a fundamental role in platelet function so that platelet alloantibodies may 
not only cause thrombocytopeni~ but may also affect primary haemostasis. (Hoffbrand et 
al., 1999) 
Moreover, HPA antibodies have been found in approximately 20% of alloimmunized 
patients. (Kiefel et al., 200 l) 
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The HLA class 1 molecules constitute the third group of platelet alloantigens. These 
antigens are heterodimeric membrane glycoproteins that consist of a 44-kD highly 
polymorphic heavy chain and a 12-kD invariant 62-microglobulin. These two 
polypeptides are noncovalently associated with each other and are present in varying 
quantities on most cells in an individual. The genes encoding HLA heavy chains are 
located at three different loci (A, 8 and C) of chromosome 6. On platelets, the expression 
ofHLA-A and B antigens is higher than that ofHLA-C antigens. (Santoso et al, 2003) 
Functionally, HLAs play a major role in presenting antigenic peptides to cytotoxic T 
lymphocytes (CTLs) (Zinkemagel et al, 1979) and are essential for the ontogenetic 
development of CDS+ cytotoxic T cells in the thymus. The expression of HLA antigens 
on platelets can vary substantially and is influenced by gene dosage and other as yet 
uncharacterised genetic factors (Liebert et al, 1979) Antibodies to HLAs are responsible 
for greater than 90o/o of immune-mediated platelet transfusion refractoriness. (Mcfarland, 
1996). 
The most common platelet reactive antibodies in transfused patients recognize epitopes 
on HLA class I molecules which are frequently responsible for febrile nonhemolytic 
transfusion reactions and immunologically mediated PTR. Although most cases of 
antibody-mediated PTR related to HLA class I, additional platelet specific antibodies 
have been identified in sera of transfused patients. 
17 
Risk factors for developing HLA antibodies include the presence of more than 1 million 
donor leucocytes in transfused products, transfusing ABO-mismatched platelets, the 
presence of an intact immune system (ie absence of cytotoxic or immunosuppressive 
therapy), female sex (approximately 75% of cases), and a history of multiple transfusions 
(>20). (Sepulveda et al., 2001) 
Refractoriness to platelet transfusion that accompanies alloimmunization is one of the 
most serious and most difficult to manage among transfusion therapy hazards. It occurs 
when a patient receives platelet preparation from another person that contains leucocytes. 
The body reacts to the leucocytes and develops antibodies against them (HLA antibodies). 
This immune response, called alloimmunization, can cause patients to become refractory 
(resistant) to subsequent platelet transfusions. This means that they do not respond or 
benefit from the transfusion, whereby the risk of spontaneous bleeding from the patient. 
Patients receiving leucocyte-reduced blood products are at much lower risk for 
refractoriness to platelet transfusion than the recipients of blood that is not leucocyte 
reduced. (K.ruskall, 1997) 
There are clinical syndromes associated with platelet alloimmunization: 
1. Human leucocyte antigens alloimmunization causes refractoriness to platelet 
transfusion. This can be reduced by the use of leucocyte-depleted blood 
components. There are few reported cases of refractoriness due to HP A 
alloimmunization. 
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2. Human platelet antigen alloimmunization causes NAIT and PTP. Most HP As 
have been implicated in NAIT. Furthermore, HP As which is associated on GPIIb-
IIIa are primarily, if not exclusively, involved in PTP, and the immunochemical 
properties of this complex may be related to the mechanism of platelet destruction 
in PTP. (Hoftbrand et al., 1999) 
Patients not previously sensitized to develop anti-platelet antibodies approximately 3-4 
weeks ( 1 0 days to 26 days) after the transfusion and patients previously immunized by 
transfusion, pregnancy, or organ transplantation, anamnestic responses occur as early as 4 
days after transfusion. Macrophages in the liver, spleen, and other tissues of the 
mononuclear phagocyte system phagocytize and destroy antibody-coated platelets. 
(Sepulveda et al., 2001) 
Other than alloimmunization to platelet antigens, there is also alloimmunization to red 
cells and granulocytes in multiply transfused patients. (Sepulveda et al., 2001) 
Approxin1ately 20-85% of patients who receive multiple transfusions become immunized 
against platelet antigens ( eg HLA, HP A) and approximately 30% of patients who are 
alloin1munized develop refractoriness to platelet transfusions (Sepulveda et al., 2001 ). 
Refractoriness may be caused by immune causes as well whereby the antibodies present 
in the patient's serum, which can react with antigens present on the platelet membrane 
and decrease platelet in vivo survival and function. (Rebulla, 2002). In approximately 
66% of these patients, non immune factors such as sepsis, antibiotics (for example 
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amphotericin), hypersplenism, fever, active bleeding and DIC alone are the cause 
' 
whereas alloimmunization may be involved in 33% of refractory patients, often in 
combination with nonimmune causes. (Sepulveda et al., 2001) 
Refractoriness to platelet transfusion is most commonly seen in patients with 
haematologic diseases requiring frequent red blood cell and platelet transfusions. Platelet 
refractoriness is not frequently seen in surgical patients, who may require less prolonged 
and intense platelet support than haematology and oncology recipients. (Kaneda et al., 
1999) 
Frequently, patients with refractorine-ss to platelet transfusion are asymptomatic and 
diagnosed by laboratory methods; however, failure to achieve hemostatic levels of 
platelets may preclude these patients from important procedures, including bone 1narrow 
transplantation. Alloimmunization should be avoided at all costs in candidates for bone 
marrow transplantation. In platelet refractoriness patients, preexisting bleeding resulting 
from thrombocytopenia may persist after transfusion of an appropriate therapeutic dose 
of platelets and rarely, spontaneous bleeding may occur after prophylactic transfusion of 
platelets. (Sepulveda et al., 2001) 
But it should be remembered that platelet transfusions in a bleeding patients are usually 
associated with very low post-transfusion platelet count increments. Nonetheless, such 
transfusions are considered a success if they are associated with cessation of bleeding. 
(Rebulla, 2002) 
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In general, alloimmunization results in the rapid removal of platelets and in lower counts 
at 10 minutes to 1 hour post-transfusion, whereas nonimmune causes mostly affect the 4-
to 24-hour post-transfusion count. Mild alloimmunization, however, can be present with 
1-hour increments within the reference range. (Sepulveda et al., 2001) 
Strategies to overcome platelet transfusion refractoriness include the selection of platelets 
from HLA-identical or HLA-compatible donors from HLA-typed donor registries, 
(Yankee et al, 1969), platelet cross-matching (Murphy et al, 1998), and the antibody 
specificity prediction method (Petz et al., 2000). 
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1.6. The immune response 
This immune response can be due to human platelet antigens and human leucocyte 
antigens. 
1.6.1. Immune response to Human platelet antigens 
An immune response to HP As is an exception rather than a rule. The most frequently 
occurring antibody is anti-HPA-Ia which is found in 80-90% of cases. Anti HPA-Sb 
occurs in 10-15% of the cases, and there are only occasional detections of antibodies to 
the other HP As. These antibodies almost always occurs in women who have been 
immunized by pregnancy or in association with PTP. The increased use of platelet 
transfusion since the early 1980s has not altered this situation; there are few reported 
cases of refractoriness due to platelet specific alloantibodies, and the incidence and 
specificity of these alloantibodies in this situation is still uncertain. Although anti-HP A-Ia 
is the most frequently encountered antibody:- less than 10% of HPA-Ia-negative 
individuals who are exposed to HPA-Ia become immunized. (Hofibrand et al., 1999) 
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1.6.2. Immune response to Human leucocyte antigens 
Alloimmunization to HLA associated with platelet transfusions is caused by the 
passenger leucocytes especially the donor dendritic cells, which directly activate the 
recipients helper T -lymphocytes. Platelets alone seem to be unable to induce primary 
antibody responses against HLA antigens, due to the absence of HLA class II antigens. 
(Hoffbrand et al, 1999) 
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Figure 1.2 Dual route of sensitization by allo-antigen. (Adapted from Hoffbrand et 
al., 1999) 
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1. 7. Laboratory detection of platelet aUoantibody. 
1.7.1 Enzyme Linked Immuno-Sorbant Assay (ELISA) 
The basic principle of ELISA is to use an enzyme to detect the binding of antigen (Ab) 
and antibody (Ab ). The enzyme converts a colourless substrate (chromogen) to a 
coloured product, indicating the presence of antigen:antibody binding. An ELISA can be 
used to detect either the presence of antibodies or antigens in a sample, depending on 
how the test is designed. 
If the test is designed to detect Abs in a sample: 
I. Combine Ag and Ab; allow them to bind: 
- the antigen is firmly attached to a surface (usually plastic well or filter) 
- sample being tested is added , allowed to incubate , then unbound Abs 
are washed from the surface. 
2. Detect Ag:Ab binding: 
- an antiglobulin that is covalently attached to an enzyme (ie enzyme-
linked) is added, incubated, then unbound antiglobulins are 
washed from the well. 
- a colourless substrate of the enzyme is added 
-if the enzyme-linked antiglobulin bound to Abs on the surface, the 
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